Attached files
| file | filename |
|---|---|
| EX-31.1 - EX-31.1 - Beam Therapeutics Inc. | beam-ex311_18.htm |
| EX-31.2 - EX-31.2 - Beam Therapeutics Inc. | beam-ex312_19.htm |
| EX-32.2 - EX-32.2 - Beam Therapeutics Inc. | beam-ex322_20.htm |
| 10-Q - 10-Q - Beam Therapeutics Inc. | beam-10q_20200331.htm |
Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with this Quarterly Report of Beam Therapeutics Inc. (the “Company”) on Form 10-Q for the period ending March 31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
|
|
(1) |
The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
|
|
(2) |
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
|
By: |
|
/s/ John Evans |
|
|
|
|
|
John Evans |
|
|
|
|
Chief Executive Officer |
|
|
|
|
(Principal executive officer) |